Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Residual cardiovascular risk persists in atherosclerotic cardiovascular disease (ASCVD) patients despite statin therapy.
• Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) offer additional risk reduction.
• Comparative effectiveness data across different PCSK9i regimens is limited.

Purpose of the Study:

• To systematically review and perform a network meta-analysis of randomized controlled trials (RCTs) on PCSK9 inhibitors in ASCVD patients.
• To compare the efficacy of different approved PCSK9i dosages in reducing major adverse cardiovascular events (MACE) and other secondary outcomes.
• To evaluate the comparative effectiveness of PCSK9 inhibitors based on achieving lower low-density lipoprotein cholesterol (LDL-C) levels.

Main Methods:

• Systematic review and network meta-analysis of eight RCTs involving 49,847 patients with ASCVD.
• Primary outcome: major adverse cardiovascular events (MACE).
• Secondary outcomes: myocardial infarction, stroke, coronary revascularization, cardiovascular mortality, and all-cause death.

Main Results:

• Evolocumab and high-dose alirocumab significantly reduced MACE compared to placebo.
• Evolocumab showed reductions in myocardial infarction, stroke, and revascularization.
• High-dose alirocumab demonstrated superior efficacy in revascularization reduction compared to evolocumab and lower-dose alirocumab.
• No PCSK9i regimen significantly reduced cardiovascular or all-cause mortality.

Conclusions:

• PCSK9 inhibitors are effective in managing ASCVD, with generally comparable efficacy across agents.
• Regimens that achieve lower and sustained LDL-C levels may provide greater cardiovascular benefits, supporting the "lower is better" principle.
• Further research may focus on optimizing PCSK9i selection and dosing strategies for maximal risk reduction in ASCVD.